Connect public, paid and private patent data with Google Patents Public Datasets

Therapeutic uses and delivery systems of dehydroepiandrosterone

Info

Publication number
CA2154161A1
CA2154161A1 CA 2154161 CA2154161A CA2154161A1 CA 2154161 A1 CA2154161 A1 CA 2154161A1 CA 2154161 CA2154161 CA 2154161 CA 2154161 A CA2154161 A CA 2154161A CA 2154161 A1 CA2154161 A1 CA 2154161A1
Authority
CA
Grant status
Application
Patent type
Prior art keywords
precursors
treatment
dehydroepiandrosterone
administration
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2154161
Other languages
French (fr)
Other versions
CA2154161C (en )
Inventor
Fernand Labrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endorecherche Inc
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0011Androstane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Abstract

Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment and/or prevention of vaginal atrophy, hypogonadism, diminished libido, osteoporosis, urinary incontinence, ovarian cancer, uterine cancer, skin atrophy, for contraception, and, in combination with an estrogen and/or progestin, for the treatment of menopause. The precursors may be formulated for percutaneous or transmucosal administration. Gels, solutions, lotions, creams, ointments and transdermal patches for the administration of these precursors are provided, as are certain pharmaceutical compositions and kits which can be used for the prevention and treatment of a wide variety of conditions related to decreased secretion of sex steroid precursors by the adrenals.
CA 2154161 1993-01-19 1994-01-19 Therapeutic uses and delivery systems of dehydroepiandrosterone Expired - Lifetime CA2154161C (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US561993 true 1993-01-19 1993-01-19
US08/005,619 1993-01-19
US08/180,361 1994-01-18
US08180361 US5776923A (en) 1993-01-19 1994-01-18 Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
PCT/CA1994/000022 WO1994016709A3 (en) 1993-01-19 1994-01-19 Therapeutic uses and delivery systems of dehydroepiandrosterone

Publications (2)

Publication Number Publication Date
CA2154161A1 true true CA2154161A1 (en) 1994-08-04
CA2154161C CA2154161C (en) 2006-12-12

Family

ID=21716809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2154161 Expired - Lifetime CA2154161C (en) 1993-01-19 1994-01-19 Therapeutic uses and delivery systems of dehydroepiandrosterone

Country Status (5)

Country Link
US (6) US5776923A (en)
CN (3) CN1954804A (en)
CA (1) CA2154161C (en)
DK (1) DK1382340T3 (en)
EP (1) EP1382340B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021323A1 (en) * 2007-08-10 2009-02-19 Endorecherche, Inc. Dhea compositions for treating menopause
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
RU2221569C2 (en) * 1998-06-11 2004-01-20 Андорешерш, Инк. ANDROST-5-ENE-3β,17β-DIOL-CONTAINING PHARMACEUTICAL COMPOSITIONS AND ITS USING
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
EP2233141A1 (en) 1999-03-18 2010-09-29 Genelabs Technologies, Inc. Ppharmaceutical compositions coprising polymorphic forms of dehydroepiandrosterone
US6726673B1 (en) * 1999-05-24 2004-04-27 Zars, Inc. Methods and apparatus for improved administration of testosterone pharmaceuticals
EP1187618A1 (en) * 1999-06-04 2002-03-20 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
FR2799645B1 (en) * 1999-10-13 2004-04-30 Oreal Use of DHEA or its metabolic precursors or derivatives as a depigmenting
US6846496B1 (en) 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
US6605591B1 (en) 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
FR2803519B1 (en) * 2000-01-12 2002-03-22 Assist Publ Hopitaux De Paris Oral use of dehydroepiandrosterone, its precursors and its derivatives to improve the weathered appearance of the skin
EP1251855A1 (en) * 2000-01-28 2002-10-30 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
US7241753B2 (en) 2000-02-25 2007-07-10 Loria Roger M Method of treatment of prostate cancer
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
FR2807323A1 (en) 2000-04-10 2001-10-12 Oreal Composition, in particular cosmetic, comprising a steroid and a 2-alkyl alkanol or ester
EP1289519A4 (en) * 2000-05-26 2005-04-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2423899T3 (en) * 2000-08-30 2013-09-25 Unimed Pharmaceuticals, Llc Method to increase testosterone levels and related steroids in women
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
DK1315502T3 (en) * 2000-08-30 2010-07-19 Unimed Pharmaceuticals Llc A method for the treatment of erectile dysfunction and to increase the libido of men
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
WO2002051421A3 (en) * 2000-12-22 2002-11-07 August Wolff Gmbh & Co Dr Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism
US20030119800A1 (en) * 2001-06-18 2003-06-26 Manolagas Stavros C. Bone anabolic compounds and methods of use
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
WO2003005954B1 (en) * 2001-07-09 2003-12-04 Zonagen Inc Methods and materials for the treatment of testosterone deficiency in men
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
FR2827764B1 (en) * 2001-07-27 2005-08-19 Oreal Composition, in particular cosmetic, comprising a steroid and a glycol
FR2828100B1 (en) * 2001-08-02 2004-09-24 Galderma Res & Dev inverse emulsion composition containing DHEA and / or its precursors or derivatives, and its uses in cosmetics and dermatology
EP1350541A1 (en) * 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Use of dehydroepiandrosterone and an estradiol derivative for preparing a medicament for treating postmenopausal climacteric disorders
WO2003090754A9 (en) * 2002-04-23 2004-06-10 Sahltech Ab Use of dhea for treatment of female hypopituitarism
WO2004035739A3 (en) * 2002-10-16 2004-09-30 James T Dalton Treating androgen decline in aging male (adam)-associated conditions with sarms
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2005039531A1 (en) 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US20050239826A1 (en) * 2004-04-14 2005-10-27 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US20080242726A1 (en) * 2004-07-14 2008-10-02 Podolski Joseph S Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol
CN101115477A (en) * 2005-02-04 2008-01-30 雷普罗斯治疗公司 Methods and materials with trans-clomiphene for the treatment of male infertility
US8247456B2 (en) * 2005-03-22 2012-08-21 Repros Therapeutics Inc. Dosing regimes for trans-clomiphene
US20090221544A1 (en) 2005-03-24 2009-09-03 Emory University Methods for the treatment of a traumatic central nervous system injury via a tapered administration protocol
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
CN101217874B (en) 2005-04-12 2012-06-06 优尼麦德药物股份有限公司 Method of treating or preventing bone deterioration or osteoporosis
US8084446B2 (en) * 2005-04-26 2011-12-27 Eric Marchewitz Use of DHEA derivatives for enhancing physical performance
WO2006125642B1 (en) 2005-05-27 2007-01-25 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
EP1937276B1 (en) 2005-10-12 2012-11-21 Unimed Pharmaceuticals, LLC Improved testosterone gel and method of use
WO2007070067A1 (en) * 2005-12-16 2007-06-21 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
CN101896174B (en) 2007-10-16 2012-10-31 利普生物药剂公司 Trans-clomiphene for metabolic syndrome
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US20130231317A1 (en) * 2011-07-19 2013-09-05 Michael S. Riepl Dhea bioadhesive controlled release gel
WO2013098592A1 (en) 2011-12-29 2013-07-04 Universidad De Chile Vaginal ring which includes dhea or dhea sulphate and optionally an agent for modulating the release of the active principle, which can be used to increase the ovarian reserve in women and to relieve symptoms associated with menopause
CN102631677A (en) * 2012-04-19 2012-08-15 中国农业大学 Pharmaceutical composition for preventing and/or treating atherosclerosis
CN104994877A (en) 2012-11-02 2015-10-21 利普生物药剂公司 Trans-clomiphene for use in cancer therapy
US20150313956A1 (en) * 2014-05-05 2015-11-05 Napier Consulting Llc Compositions and methods for hair growth

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643046B2 (en) * 1967-10-04 1975-11-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951B1 (en) * 1971-08-09 1982-11-23
JPS505372A (en) * 1973-05-30 1975-01-21
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
DE2534911C2 (en) * 1975-08-01 1985-04-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De
US4213978A (en) * 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
FR2518879B3 (en) * 1981-12-30 1985-02-08 Besins Jean
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
CA1211430A (en) * 1983-05-30 1986-09-16 Sten K. Kristensson Steroid esters preparation
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
DE3333240A1 (en) * 1983-09-12 1985-03-28 Schering Ag Preparation for transdermal application of drug active ingredients
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4812447A (en) * 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US5135480A (en) * 1986-07-10 1992-08-04 Elan Transdermal Limited Transdermal drug delivery device
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
NL194728C (en) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals A pharmaceutical composition suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof.
US4835147A (en) * 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US5162037A (en) * 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
EP0371496A1 (en) * 1988-12-01 1990-06-06 Schering Corporation Compositions for transdermal delivery of estradiol
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
JP2959838B2 (en) * 1989-03-10 1999-10-06 アンドルシェルシュ・インコーポレイテッド Combination therapy for the treatment of estrogen-sensitive disease
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5434146A (en) * 1991-06-28 1995-07-18 Endorecherche, Inc. Controlled release systems and low dose androgens
US5362720A (en) * 1991-06-28 1994-11-08 Endorecherche, Inc. Methods of treating or preventing breast or endometrial cancer with low dose non-masculinizing androgenic compounds

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
WO2009021323A1 (en) * 2007-08-10 2009-02-19 Endorecherche, Inc. Dhea compositions for treating menopause
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US8629129B2 (en) 2007-08-10 2014-01-14 Endorecherche, Inc. Pharmaceutical compositions
US8957054B2 (en) 2007-08-10 2015-02-17 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date Type
US5922700A (en) 1999-07-13 grant
US5780460A (en) 1998-07-14 grant
US5955455A (en) 1999-09-21 grant
DK1382340T3 (en) 2006-08-14 grant
EP1382340A1 (en) 2004-01-21 application
CN101444519A (en) 2009-06-03 application
CN1954804A (en) 2007-05-02 application
CN102357247A (en) 2012-02-22 application
US5728688A (en) 1998-03-17 grant
CA2154161C (en) 2006-12-12 grant
US5776923A (en) 1998-07-07 grant
EP1382340B1 (en) 2006-04-05 grant
US5824671A (en) 1998-10-20 grant

Similar Documents

Publication Publication Date Title
Segaloff The enhanced local androgenic activity of 19-nor steroids and stabilization of their structure by 7α-and 17α-methyl substituents to highly potent androgens by any route of administration
Groom et al. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women
Sitruk-Ware New progestogens
US5955454A (en) Nasal pharmaceutical composition containing a progestogen
US5898032A (en) Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
Eisenberg et al. The levator ani muscle of the rat as an index of myotrophic activity of steroidal hormones
US5478566A (en) Stimulation of cytokine production
US5807849A (en) Therapeutic methods and delivery systems utilizing sex steroid precursors
US5552394A (en) Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
Oelkers Drospirenone, a progestogen with antimineralocorticoid properties: a short review
Stanczyk All progestins are not created equal
US4145416A (en) Novel agents and novel methods for treatment of climacteric disturbances
US5387583A (en) Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5719136A (en) Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women
US20040186086A1 (en) Use of estrogen compounds to increase libido in women
US5763433A (en) Pharmaceutical compositions containing 3-beta-hydroxylated 6,7-substituted steroid derivatives, and use thereof
Paulsen Progestin metabolism: special reference to estrogenic pathways
US4071625A (en) 19-Oxygenated-5α-androstanes for the enhancement of libido
Foster et al. Dienogest
Philibert et al. The pharmacological profile of a novel norpregnane progestin (trimegestone)
Batukan et al. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism
Epstein et al. Comparative pharmacological and clinical activity of 19‐nortestosterone and 17‐hydroxyprogesterone derivatives in man
Krattenmacher Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
WO1996019997A1 (en) Compounds with progesterone-antagonistic and anti-oestrogen properties intended for combined use in female contraception
US5569652A (en) Dihydrospirorenone as an antiandrogen

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140120